Switch theme
Sign up to access all valuation multiples
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.
1926
4.6K+
LTM Revenue $3.0B
LTM EBITDA $1.1B
$15.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Recordati has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of $1.1B.
In the most recent fiscal year, Recordati achieved revenue of $2.8B and an EBITDA of $937M.
Recordati expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Recordati valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $2.0B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $1.1B | XXX | $937M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $850M | XXX | $777M | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $547M | XXX | $491M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Recordati's stock price is EUR 52 (or $62).
Recordati has current market cap of EUR 10.8B (or $12.7B), and EV of EUR 12.8B (or $15.1B).
See Recordati trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.1B | $12.7B | XXX | XXX | XXX | XXX | $3.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Recordati has market cap of $12.7B and EV of $15.1B.
Recordati's trades at 5.5x EV/Revenue multiple, and 16.1x EV/EBITDA.
Equity research analysts estimate Recordati's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Recordati has a P/E ratio of 23.2x.
See valuation multiples for Recordati and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.7B | XXX | $12.7B | XXX | XXX | XXX |
| EV (current) | $15.1B | XXX | $15.1B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBIT | 17.7x | XXX | 19.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.2x | XXX | 25.8x | XXX | XXX | XXX |
| EV/FCF | 27.8x | XXX | -45.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRecordati's last 12 month revenue growth is 9%
Recordati's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Recordati's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Recordati's rule of X is 61% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Recordati and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recordati acquired XXX companies to date.
Last acquisition by Recordati was XXXXXXXX, XXXXX XXXXX XXXXXX . Recordati acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Recordati founded? | Recordati was founded in 1926. |
| Where is Recordati headquartered? | Recordati is headquartered in Italy. |
| How many employees does Recordati have? | As of today, Recordati has 4.6K+ employees. |
| Who is the CEO of Recordati? | Recordati's CEO is Mr. Robert Koremans. |
| Is Recordati publicy listed? | Yes, Recordati is a public company listed on MIL. |
| What is the stock symbol of Recordati? | Recordati trades under REC ticker. |
| When did Recordati go public? | Recordati went public in 1984. |
| Who are competitors of Recordati? | Similar companies to Recordati include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Recordati? | Recordati's current market cap is $12.7B |
| What is the current revenue of Recordati? | Recordati's last 12 months revenue is $3.0B. |
| What is the current revenue growth of Recordati? | Recordati revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Recordati? | Current revenue multiple of Recordati is 5.1x. |
| Is Recordati profitable? | Yes, Recordati is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Recordati? | Recordati's last 12 months EBITDA is $1.1B. |
| What is Recordati's EBITDA margin? | Recordati's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Recordati? | Current EBITDA multiple of Recordati is 13.8x. |
| What is the current FCF of Recordati? | Recordati's last 12 months FCF is $541M. |
| What is Recordati's FCF margin? | Recordati's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Recordati? | Current FCF multiple of Recordati is 27.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
